1차 출처 기록
결정급탑라인 결과
Invivyd, VYD2311 3상 주요 데이터 2026년 3분기 말 예상
The company now guides for top-line data from the DECLARATION and LIBERTY Phase 3 studies of VYD2311 around the end of Q3 2026. Upon readout, Invivyd plans to either fully unblind and file a traditional BLA or partially unblind and file for Accelerated Approval based on antiviral activity and safety, with a confirmatory cohort post-approval.
핵심 사실
출처 발췌
EX-99.1 3 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY • Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy • Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director • Ian Sheffield appointed to Invivyd’s Board of Directors as an independent director • DECLARATION and LIBERTY studies of VYD2311 approaching completion with further updates expected within weeks NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, cur